002550 On Other Exchanges
Symbol
Exchange
Shenzhen

changzhou qianhong biophar-a (002550) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHANGZHOU QIANHONG BIOPHAR-A (002550)
\

Related News

No related news articles were found.

changzhou qianhong biophar-a (002550) Related Businessweek News

No Related Businessweek News Found

changzhou qianhong biophar-a (002550) Details

Changzhou Qianhong Biopharma Co.,Ltd engages in the research and development, production, and sale of bio-pharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various API products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid. It also offers a range of preparations, such as nadroparin calcium PFS, enoxaparin sodium PFS, dalteparin sodium PFS, and asparaginase and heparin sodium injections for use as anticoagulants. The company provides its products in the form of small volume parenteral solutions, tablets, hard capsules, granules, and APIs. It also exports its products. Changzhou Qianhong Biopharma Co.,Ltd was founded in 1971 and is based in Changzhou, China.

1,255 Employees
Last Reported Date: 04/23/19
Founded in 1971

changzhou qianhong biophar-a (002550) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

changzhou qianhong biophar-a
Changzhou Qianhong Biopharma Co.,Ltd Announces the Final Cash Dividend for the Year 2018, Payable on May 28, 2019

Changzhou Qianhong Biopharma Co.,Ltd announced the final cash dividend (tax included) of CNY 1.2 per 10 A shares for the year 2018. The dividend is payable on May 28, 2019 to the shareholders record on May 27, 2019 and ex-date is on May 28, 2019.

Changzhou Qianhong Biopharma Co.,Ltd Announces Final Cash Dividend for the Year 2018; Announces Amendments to the Articles of Association

Changzhou Qianhong Biopharma Co.,Ltd announced final cash dividend of CNY 1.20000000 per 10 shares (tax included) for the year 2018. The announced amendments to the articles of association at its AGM held on May 15, 2019.

Changzhou Qianhong Biopharma Co.,Ltd Proposes Amendments to the Articles of Association

Changzhou Qianhong Biopharma Co.,Ltd proposed amendments to the articles of association at its AGM to be held on May 15, 2019.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

002550 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002550.
View Industry Companies
 

Industry Analysis

002550

Industry Average

Valuation 002550 Industry Range
Price/Earnings 26.0x
Price/Sales 4.3x
Price/Book 2.2x
Price/Cash Flow 25.4x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHANGZHOU QIANHONG BIOPHAR-A, please visit www.qhsh.com.cn. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.